Hormone composition

Abstract

Twice weekly administration of an analog to a Vagifem tablet which only contains 10 μg of active material has a sufficient effect.

1 . A method for treating atrophic vaginitis in a patient in need of such treatment, said method comprising administering vaginally to said patient an amount of about 10 μg estradiol, wherein administration of said amount occurs once or twice per week.  
     
     
         2 . A method according to  claim 1 , wherein the patient is a menopausal or post-menopausal woman.  
     
     
         3 . A method according to  claim 1 , wherein no progestogen is administered.  
     
     
         4 . A method according to  claim 1 , wherein said at least once-weekly administration occurs over a time period of more than two weeks.  
     
     
         5 . A method according to  claim 4 , wherein said period of time is more than 3 months.  
     
     
         6 . A method according to  claim 1 , wherein said estradiol is administered in tablet form and wherein each tablet comprises, in addition to estradiol or a therapeutically equivalent amount of a salt thereof, hypromellose, lactose monohydrate, maize starch, and magnesium stearate.  
     
     
         7 . A method according to  claim 6 , wherein said tablet comprises about 60-80% w/w hypromellose; 20-25% w/w lactose; about 5-15% maize starch; and about 0.2-1.5% magnesium stearate.  
     
     
         8 . A method for treating atrophic vaginitis in a patient in need of such treatment, said method comprising administering vaginally to said patient a tablet comprising hypromellose, lactose monohydrate, maize starch, and magnesium stearate.  
     
     
         9 . A method according to  claim 8 , wherein said tablet comprises about 60-80% w/w hypromellose; 20-25% w/w lactose; about 5-15% maize starch; and about 0.2-1.5% magnesium stearate.